Drug-induced granulomatosis is dupilumab the new kid on the block?

Archive ouverte

Belhomme, N | Gaignon, T | Jouneau, S | Misery, L | Abasq-Thomas, C | Cador, B | Lecureur, V | Cadiou, S | Ballerie, A | Polard, E | Mensi, S | Jego, P | Lescoat, A

Edité par CCSD ; Wiley -

International audience. Dupilumab is an IgG4 antibody directed toward IL-4 and IL-13, two major effectors of the Th2 immunity response. It was originally developed for severe and/or refractory atopic dermatitis, nevertheless its use has secondarily been broadened to severe asthma . We report herein the case a 28-year-old, non-smoker male who presented to the emergency department with confusion, headaches, emesis and photophobia. His medical history included only a severe atopic dermatitis leading to dupilumab initation 4 months earlier. Physical examination revealed a meningoencephalitis syndrome, and a bilateral parotidomegaly.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion